Survivin在造血系统肿瘤中的研究进展  

Advance of Research on Survivin in Hematological Malignancies——Review

作　　者：熊辉霞[1] 陈宝安[1] 丁家华[1] 

机构地区：[1]东南大学附属中大医院血液科,南京210009

出　　处：《中国实验血液学杂志》2004年第6期866-869,共4页Journal of Experimental Hematology

摘　　要：Survivin是一种新的凋亡抑制蛋白 (inhibitorofapoptosisprotein ,IAP ) ,具有细胞周期调控和凋亡抑制双重功能。在多种造血系统肿瘤组织中高表达 ,与诊断、预后和耐药密切相关。利用survivin致敏的树突状细胞疫苗、survivin反义核酸及Survivin阴性突变体可有效抑制肿瘤细胞生长 ,为采用生物学策略治疗造血系统肿瘤开辟了新途径。本综述重点阐述了survivin在造血系统肿瘤中的表达 ,survivin与造血系统肿瘤预后和耐药的关系及survivin在造血系统肿瘤治疗中的应用。Survivin a novel member of the inhibitor of apoptosis protein family, is overexpressed in most types of cancer but not in normal differentiated adult tissues. Its mRNA expression levels among hematogical malignancies are characteristic in each type, subtype and distinctive in different phases of disease, making it a reliable diagnostic marker for clinical stages. Recently, researches indicate that high levels of survivin expression are associated with a poor prognosis and may be involved in tumor resistance to multiple chemotherapeutic drugs. In addition, experiments demonstrate that leukemic vaccination with DC pulsed with survivin antigen in vitro inhibit the proliferation of leukemic cells. Furthermore, when transferred survivin antisense oligodeoxynucleotide or dominant negative mutant survivin into, malignant cells can be induced apoptosis mediated by downregulation in survivin expression. These findings suggest that survivin may serve as a potential target for biological strategies against hematological neoplasms. This review focuses on expression of survivin in hematological malignancies, effects of survivin on drug resistance and prognosis of hematological malignancies, and application of survivin in the treatment of hematological malignancies.

关 键 词：SURVIVIN 造血系统肿瘤 耐药 生物治疗 

分 类 号：R730.3[医药卫生—肿瘤] R730.54[医药卫生—临床医学]